Table 2.
Vaccine effectiveness against COVID-19-related outcomes and mortality among individuals with different vaccination status
| Unvaccinated | 1 dose only |
2 doses only |
3 doses |
||||||
|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 | CoronaVac | All BNT162b2 | All CoronaVac | All BNT162b2 | All CoronaVac | B-B-C | C-C-B | ||
| COVID-19 infection | |||||||||
| MM | |||||||||
| Case | 25390 | 2981 | 15628 | 14781 | 27071 | 4752 | 8591 | 72 | 2161 |
| Control | 81703 | 13927 | 51934 | 67881 | 99073 | 36747 | 39895 | 333 | 13154 |
| VE % | REF | 31.5 (28.6–34.4) | −0.1 (−2.4 to 2.2) | 29.7 (27.9–31.3) | 9.1 (7.2–11.0) | 58.8 (57.3–60.2) | 29.4 (27.3–31.4) | 33.1 (13.5–48.3) | 47.3 (44.7–49.9) |
| No MM | |||||||||
| Case | 43409 | 16799 | 26013 | 132097 | 94026 | 36094 | 49088 | 559 | 13400 |
| Control | 97989 | 39176 | 50304 | 257530 | 143436 | 120901 | 80308 | 1137 | 32063 |
| VE % | REF | 1.9 (−0.3 to 4.0) | −21.9 (−24.3 to −19.5) | −15.4 (−17.0 to −13.9) | −54.0 (−56.3 to −51.8) | 33.4 (32.3–34.5) | −37.7 (−40.1 to −35.4) | −5.9 (−17.5 to 4.6) | 6.4 (4.1–8.6) |
| COVID-19 related hospitalization | |||||||||
| MM | |||||||||
| Case | 8859 | 507 | 3373 | 950 | 2410 | 181 | 312 | 3 | 80 |
| Control | 49000 | 5177 | 26807 | 19587 | 39029 | 9258 | 12042 | 92 | 3298 |
| VE % | REF | 49.7 (44.5–54.4) | 27.4 (24.1–30.5) | 74.9 (73.0–76.6) | 64.9 (63.1–66.6) | 90.4 (88.9–91.8) | 86.2 (84.5–87.7) | 87.1 (59.1–96.0) | 87.9 (84.8–90.4) |
| No MM | |||||||||
| Case | 6249 | 670 | 2463 | 3215 | 3339 | 514 | 713 | 9 | 161 |
| Control | 35927 | 7052 | 16751 | 41066 | 35168 | 15815 | 15123 | 170 | 4746 |
| VE % | REF | 49.7 (45.2–53.9) | 11.7 (6.9–16.2) | 59.0 (56.9–60.9) | 46.4 (43.9–48.9) | 83.8 (82.2–85.3) | 75.0 (72.8–77.0) | 75.3 (51.5–87.4) | 82.9 (79.9–85.5) |
| COVID-19 related mortality | |||||||||
| MM | |||||||||
| Case | 3688 | 87 | 962 | 103 | 483 | 10 | 34 | 0 | 4 |
| Control | 17836 | 1565 | 9946 | 4726 | 12139 | 2309 | 3390 | 18 | 786 |
| VE % | REF | 73.4 (66.6–78.9) | 48.9 (44.6–52.9) | 89.3 (86.8–91.3) | 79.2 (76.9–81.3) | 97.9 (96.0–98.9) | 94.9 (92.7–96.4) | NA | 97.5 (93.2–99.1) |
| No MM | |||||||||
| Case | 1450 | 41 | 485 | 56 | 270 | 12 | 7 | 0 | 4 |
| Control | 6924 | 637 | 3806 | 2279 | 5115 | 1497 | 1846 | 23 | 497 |
| VE % | REF | 76.3 (66.4–83.3) | 39.1 (31.3–45.9) | 91.3 (88.4–93.5) | 77.1 (73.5–80.2) | 97.5 (95.5–98.6) | 98.6 (97.1–99.4) | NA | 97.2 (92.3–99.0) |
MM, multimorbidity; VE, vaccination effectiveness; CI, confidence interval.